Low-dose oral sirolimus appears to increase the risk of menstrual-cycle disturbances and ovarian cysts. Monitoring patients for sirolimus-associated ovarian toxicity may be considered.
CITATION STYLE
Braun, M., Young, J., Reiner, C. S., Poster, D., Wüthrich, R. P., & Serra, A. L. (2012). Ovarian Toxicity from Sirolimus. New England Journal of Medicine, 366(11), 1062–1064. https://doi.org/10.1056/nejmc1113145
Mendeley helps you to discover research relevant for your work.